Discussion: There are no references in the discussion, and the results are not discussed as compared to previous studies. Limitations of the study: The retrospective design is the major limitation in the study and not discussed sufficiently. Only the problem with missed cases is discussed. But a retrospective design normally means that information about the patient is limited, because the author had no possibility to secure complete data collection by designing questionnaires. Comorbidity, symptoms and disease severity are not easily accessed only from a patient"s journal. This is not discussed. MMSE as a tool does not give a complete overview over dementia symptoms, especially in DLB.
REVIEWER
Toshiki Uchihara Tokyo Metropolitan Institute of Medical Science, Japan REVIEW RETURNED 22-May-2017
GENERAL COMMENTS
This study confirmed an expected shorter survival of dementia with clinically diagnosed Lewy body patients (n=251) than AD counterpart (N=222) identified through retrospective search on database constructed in a district with a population of 900, 000. These data are potentially interesting and probably useful to construct a regional-care system for such aging population with dementia. However, it remains to be clarified whether these clinical diagnoses represent pathological reality. 
The manuscript has been substantially improved after revisions. However, there are still some issues that need to be addressed:
1. As I mentioned in my previous round of review, there is at least another naturalistic cohort of a large number of patients with Lewy Body dementia or DLB, which is recommend being mentioned in both "Introduction" and "Discussion" sections: In this revised version, I still couldn"t find any discussion on relevant findings from other similar studies like this one. One very important aspect of "Discussion" section, which is still missing, is to compare study findings with those of the relevant literature and other studies.
2. In the "Results" section, subsection "Survival Analysis": I recommend using "year" instead of "days" as the unit of measure for survival time. Furthermore, please calculate and report 95% confidence intervals for the hazard ratios reported in this section. 4. Since the validity of diagnosis is of great importance in naturalistic databases, I wonder if there is any data (even external) available on the reassessment of DLB and AD diagnosis in the CPFT cohort? Is there any estimation on the validity of dementia diagnosis in this database?
REVIEWER

Dag Aarsland KCL London
REVIEW RETURNED
31-May-2017
GENERAL COMMENTS
The authors used an automatized search of electronic records in secondary health care across their trust in UK to identify 252 DLB and 222 AD cases with similar characteristics expect gender. Using UK data they found a significant shorter survival (3.3 -4 yrs) in DLB compared to AD (6.7-7 yrs). Thus this finding is consistent with several previous studies. Strengths include one of the largest sample sizes and the routine care clinical setting rather than a research setting.
The study is well designed and clearly written, and conclusions well justified. I have only minor issues.
Most importantly is the diagnostic accuracy which is depending on clinicians reporting the terms Lewy or DLB or LBD.
Thus as the authors state, since many DLB cases are missed, only a subgroup is likely identified, which may be biased. They could have considered using additional relevant keywors such as «visual hallucinations» and «REM sleep behavior disorder».
Was DAT scan utilized?
The duration 3.3 yrs in male after «first assessment for cognitive impairment» is short. Likely this reflects the fact that patients are coming to diagnostic evaluation late. This may be discussed in more detail, and also a more in depth comparison with other studies in terms of total and relative survival. Some studies have failed to find difference in survival, thus differences in design between studies could be discussed. In the Abstract, please state that survival time is from first assessment.
The search first identified 983 records. It would be helpful to show a flow chart with reasons for exclusion ending up with the final number of 251.
It"s surprising that comorbidity burden was not associated with survival in DLB.Please provide some information about the instrument, and also present some more specific details in the two groups. % with «low» and «High» morbidity does not show sufficient details.
Some specific comments:
Methods:
• Page 3 line 48: Worth to mention that it is a retrospective cohort study.
• Page 5 line 32: Are age and MMSE score normally distributed. If not, use MannWhitney U or Wilcoxon Rank Sum to compare means.
• Case identification: Was there any attempt to clearly distinguish between Parkinson"s Disease Dementia and Dementia with Lewy bodies. 37% of DLB patients prescribed Parkinson"s disease drugs which seems quite high for a DLB cohort. Could some of these have PDD? No a major limitation, but worth acknowledging.
Results:
• Sample Is there any data on how many people were diagnosed with any form of dementia in CPFT in the observation period? And subsequently % of patients with AD and DLB
• Page 6 Line 43-48 Hazard ratios are sometimes presented with two or three decimal places, please harmonise. P values look highly significant, but please also give 95% CIs for the Hazard Ratios.
• Page 6 Line 42-57 (and later) Please harmonise where possible the number of decimal places of p-values and test statistics. I"d suggest three decimal places, and when lower report: p<0.001
• Page 7 Line 7 Is this referring to Figure 1 • 95% Confidence intervals are reported in various ways (CI, 95% CI, 95% confidence interval). Please harmonise.
• Initially the survival analysis is presented in days and (months), later it is presented in days and (years). Please harmonise. I"d suggest presenting days and years with one decimal place.
• Survival curves clearly demonstrate worse survival in DLB. In the results section could you also present the log rank test and p-value?
• Multivariate Cox regression models might make the relationship between survival, diagnosis and various covariates clearer. It might be more informative for the reader to have various levels of adjustment to Cox regression models: 1. Crude mortality risk for DLB compared to AD (HR, 95% CI) 2. Adjusted for age and gender 3. Adjusted for age, gender, MMSE 4. Adjusted for age, gender, MMSE, co-morbidity score 5. Adjusted for age, gender, MMSE, co-morbidity score and medications This should show how the different co-variates/potential confounders influence the relationship and could be presented as a table.
• Limitations: It"s worth adding to limitations that no information was available, regarding ethnicity, education level and levels of deprivation; and how likely this is to have affected the results given the source population. How diverse is the are covered by CPFT.
• Interpretation: A more in-depth discussion about the potential reasons for increased mortality would be informative for the reader. Which factors are actually known to predict mortality in DLB? Are they different than in AD? And how are they addressed or not addressed in the current study? The references 3-7 cited in the induction might be helpful to facilitate that.
I"d limit the conclusions regarding male predominance in DLB. In the end this study has also shown that the proportion of males is higher in DLB than AD.
• Comment: The paper presents a retrospective study based on data from patient journals, comparing the survival of patients with DLB versus AD. As other studies before, it confirms that patients with DLB have a higher mortality than AD patients. It is a sound study with a comparatively large cohort of DLB patients, and its findings are valuable.
Response: We thank the reviewer for their positive comment s and their thorough review Comment: General: readability could be improved. Some paragraphs are hard to understand, though the content is correct when reading it carefully.
Response: In the process of revising the document we have taken particular care to improve the readability throughout.
Comment: Title: This is a retrospective study. Strictly spoken, retrospective implies that it is as well a naturalistic study. However, retrospective is the correct term to describe the study design, to my opinion. This applies throughout the paper.
Response: We take this comment on board and have made the requested changes in the title and throughout Comment: Abstract: The abstract states that the outcome of DLB and AD is to be examined. But the study evaluates only survival as outcome measure. This should be corrected. 1/13 should be replaced by 7.5 %. OK Response: We have made this change as requested, though because use of the 7.5% to one decimal place implies a degree of accuracy not possible, we instead state "around 7%"
Comment: Research question: In the objective, it is mentioned that the temporal trend in diagnosis rate is to be examined, but the results presented are not detailed enough to be informative, and they are not discussed. I suggest it to be removed.
Response: We agree and have removed this as requested. . Comment: Methods: Disease duration: The setting is secondary care facilities. First visit due to cognitive impairment does probably not coincide with disease onset. Time of diagnosis is a much more reliable measurement and should be used.
Response: We thank the reviewer for this recommendation. We took first presentation with cognitive impairment rather than date of diagnosis as the starting point for the survival analysis at the request of a previous reviewer as it was suggested that date of diagnosis might introduce bias in that patients with DLB may receive diagnoses later in the disease trajectory than those with AD. However in response to this comment we have repeated the survival analysis taking date of diagnosis as the starting point and reported both results. The results are unchanged and this is stated in the paper.
Comment: Ethics approval is missing.
Response: The details of the NHS ethics approval were present in the original manuscript but we have expanded this to make it clearer.
Comment: Results: time of survival is reported sometimes in days, sometimes in months and sometimes in years. Years are most easily understood by a reader, but anyhow, the same time unit should be use throughout.
Response: We take this comment on board and have harmonised all of the units to years.
Comment: Main results, paragraph 2: The information about sex distribution should be rephrased, because it is confusing to read.
Response: We have rephrased the relevant section as requested.
Comment: Discussion: There are no references in the discussion, and the results are not discussed as compared to previous studies.
Response: We thank the reviewer for this comment and have added more detail to the discussion section as requested Comment: Limitations of the study: The retrospective design is the major limitation in the study and not discussed sufficiently. Only the problem with missed cases is discussed. But a retrospective design normally means that information about the patient is limited, because the author had no possibility to secure complete data collection by designing questionnaires. Comorbidity, symptoms and disease severity are not easily accessed only from a patient"s journal. This is not discussed.
Response: We thank the reviewer for this observation and agree that the retrospective design introduces limitations in terms of the quality and completeness of the data we were able to capture. We have modified the limitations section accordingly. Of course, these limitations need to be balanced against the strengths of the study in being able to assess all subjects in the cohort, not just selected subjects who consented to take part in a particular study.
Comment: MMSE as a tool does not give a complete overview over dementia symptoms, especially in DLB.
Response: We thank the reviewer for this comment and agree that MMSE does not give a complete description of cognitive impairment in dementia. We have added a paragraph to the limitations section to acknowledge this. Response: We acknowledge this as a limitation of ours and any study that relies on clinician diagnosis for inclusion. We had previously acknowledged this in the discussion but thank the reviewer for directing us to the relevant study and have cited this in the limitations section and added a further paragraph discussing diagnostic accuracy. Response: As with the comment above we acknowledge this limitation and have cited the study suggested in the limitations section along with further paragraph. Our study however showed a marked difference in survival between the two groups not explained by potential confounders and the results were in line with studies that have used pathologically defined cohorts. This in itself is an interesting finding and may reflect the value of expert clinician diagnosis in differentiating between the two conditions based on clinical presentation.
Comment: Because the situation is much more complicated than the authors assumed, comprehensive literature survey on autopsy series is necessary. It is, then, requested to clarify what are the potential novelties of this clinical study and its limitations. Otherwise, this study just demonstrated clinical characteristics of dementia in a region of UK.
Response: As with the previous comment we acknowledge that clinician identified diagnostic cohorts may be less diagnostically accurate than pathologically identified cohorts. We believe however that this study has value in being able to show not just clear differences between the two diagnostic groups in terms of outcomes but that the demonstration of that difference in clinical cohorts demonstrates value in assigning diagnostic labels based on the clinical criteria used for individual subjects in routine clinical practice when, by definition, pathological data are not available.
Comment: 1. Prevalence of vascular or other dementia?: It would be useful to include the rough prevalence of vascular dementia in this cohort.
Response: The identification of cases in this cohort relied on a process of screening every potentially relevant record. This process was focussed on DLB and AD only. Based on clinical coding alone we would not be able to report an accurate prevalence of vascular or other dementias in our patient population at this time, though further planned work seeks to improve case identification in dementia in clinical records.
Comment: 2. Survival of control population: Kaplan-Meier data on control population (either this cohort or UK public health data) may be useful.
Response: We agree and have obtained national data on survival in dementia and presented this in the background section.
Reviewer 3
Seyed-Mohammad Fereshtehnejad McGill University, Canada. Karolinska Institutet, Sweden
Comment: The manuscript has been substantially improved after revisions. However, there are still some issues that need to be addressed:
Response: We thank the reviewer for their positive comments and for agreeing to review the paper for a second time.
Comment: . As I mentioned in my previous round of review, there is at least another naturalistic cohort of a large number of patients with Lewy Body dementia or DLB, which is recommend being mentioned in both "Introduction" and "Discussion" sections: Garcia-Ptacek S, Farahmand B, Kåreholt I, Religa D, Cuadrado ML, Eriksdotter M. Mortality risk after dementia diagnosis by dementia type and underlying factors: a cohort of 15,209 patients based on the Swedish Dementia Registry. J Alzheimers Dis. 2014;41(2):467-77. In this revised version, I still couldn"t find any discussion on relevant findings from other similar studies like this one. One very important aspect of "Discussion" section, which is still missing, is to compare study findings with those of the relevant literature and other studies.
Response: We apologise for this oversight and have updated the discussion section with reference the paper above and findings of other studies.
Comment: 2. In the "Results" section, subsection "Survival Analysis": I recommend using "year" instead of "days" as the unit of measure for survival time. Furthermore, please calculate and report 95% confidence intervals for the hazard ratios reported in this section.
Response: We agree and have changed all of the time units to years, and added a table of results for the survival analysis that reports 95% CI for the hazard ratios Response: We thank the reviewer for highlighting this oversight and have corrected it.
Comment: 4. Since the validity of diagnosis is of great importance in naturalistic databases, I wonder if there is any data (even external) available on the reassessment of DLB and AD diagnosis in the CPFT cohort? Is there any estimation on the validity of dementia diagnosis in this database?
Response: We acknowledge the importance of diagnostic validity. We did go through process of validating the clinician diagnoses but did not adequately report this in the previous iteration.
In the DLB sample 97% of the sample met criteria for possible or probable DLB. We now present this in the results section. We thank the reviewer for their recommendation.
Reviewer 4
Dag Aarsland KCL London Comment: The authors used an automatized search of electronic records in secondary health care across their trust in UK to identify 252 DLB and 222 AD cases with similar characteristics expect gender. Using UK data they found a significant shorter survival (3.3 -4 yrs) in DLB compared to AD (6.7-7 yrs). Thus this finding is consistent with several previous studies. Strengths include one of the largest sample sizes and the routine care clinical setting rather than a research setting. The study is well designed and clearly written, and conclusions well justified.
Response: We thank the reviewer for their positive comments and their thorough review Comment: Most importantly is the diagnostic accuracy which is depending on clinicians reporting the terms Lewy or DLB or LBD. Thus as the authors state, since many DLB cases are missed, only a subgroup is likely identified, which may be biased. They could have considered using additional relevant keywors such as «visual hallucinations» and «REM sleep behavior disorder».
Response: We thank the reviewer for this observation. We have planned future work that we hope will improve case identification in DLB by identifying patients who present with symptom clusters seen in DLB with the features above as examples. However in this study we took that starting point of clinician identified DLB so that we could ascertain whether the observed poorer survival in DLB is also present in routine clinical cohorts. Our study however showed a marked difference in survival between the two groups not explained by potential confounders and the results were in line with studies that have used pathologically defined cohorts. This in itself is an interesting finding and may reflect the value of expert clinician diagnosis in differentiating between the two conditions based on clinical presentation.
Comment: Was DAT scan utilized?
Response: In the DLB cohort, only three patients had a DAT scan during the time they were under the care of CPFT (that was recorded in the clinical record).
Comment: The duration 3.3 yrs in male after «first assessment for cognitive impairment» is short. Likely this reflects the fact that patients are coming to diagnostic evaluation late. This may be discussed in more detail, and also a more in depth comparison with other studies in terms of total and relative survival. Some studies have failed to find difference in survival, thus differences in design between studies could be discussed.
Response: In the process of revising the manuscript we have reviewed the findings of other studies that examine mortality in DLB and find that our results are in line with these. We have added detail to the discussion section in discussing this in comparing our findings to those of other studies. Regarding the comment that poorer survival in patients with DLB is due to then coming to diagnostic evaluation late, we think that this is unlikely in our cohort because the mean MMSE score was in the mild to moderate range and no difference was seen between the mean scores compared with the AD cohort. There was also no difference in the mean age of the patients at diagnosis. This does not completely exclude diagnostic delay as the explanation for poorer survival but is an indicator that other factors need to be considered.
Comment: In the Abstract, please state that survival time is from first assessment.
Response: We have updated the abstract as requested with the start time of the survival analysis which is first presentation to services with cognitive impairment Comment: The search first identified 983 records. It would be helpful to show a flow chart with reasons for exclusion ending up with the final number of 251.
Response: We agree that a flowchart with detailed breakdown of reasons for exclusion would be informative. I the process of identifying cases we excluded patients for whom the chosen keywords did not relate to a given diagnosis or if the diagnosis was not the most recent. Unfortunately we did not retain electronic records for why we made the decision for each individual screened. We did however go through a process of validating each clinician identified case against diagnostic criteria though did not report this in detail in the previously submitted manuscript. We have now done this and report these data in the results section as we have indicated above.
Comment: It"s surprising that comorbidity burden was not associated with survival in DLB. Please provide some information about the instrument, and also present some more specific details in the two groups. % with «low» and «High» morbidity does not show sufficient details.
